ArticleMolecular cancer research : MCR2019
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- Abemaciclib Inhibits Retinoblastoma Tumor Growth by Targeting CDK1/2.Investigative ophthalmology & visual science · 2026Article
- Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments.Communications medicine · 2026Article
- CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers.Frontiers in immunology · 2026Review
- Expression and interaction of RNA binding protein HuR with multidrug transporters (P-GP, MRP1, and ABCG2) in chemoresistant breast and colorectal cancer cells.Journal, genetic engineering & biotechnology · 2025Article
- Extracellular transfer of HuR promotes acquired cisplatin resistance in esophageal cancer cells.Cancer biology & therapy · 2025Article
- Current progress in targeting mitotic kinases in PDAC.RSC medicinal chemistry · 2025Review
- Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward.Current issues in molecular biology · 2025Review
- Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression.Frontiers in oncology · 2025Review
- Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells.Cancers · 2024Article
- HuR controls glutaminase RNA metabolism.Nature communications · 2024Article
- Modulation of autophagy and apoptosis can contribute to the anticancer effect of Abemaciclib/Celecoxib combination in colon cancer cells.Medical oncology (Northwood, London, England) · 2024Article
- Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis.Gastroenterology · 2024Article
- Targeting the RNA-Binding Protein HuR in Cancer.Cancer research · 2023Review
- Deletion of the mRNA stability factorNAR cancer · 2023Article
- Recent advances in targeted therapy for pancreatic adenocarcinoma.World journal of gastrointestinal oncology · 2023Review
- [Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and Migration of Small Cell Lung Cancer with High c-Myc Expression].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Review
- CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA.Cancer biology & therapy · 2022Article
- Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug.Biomedicines · 2022Review
- The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ERScience advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Teena Dhir *Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Christopher W Schultz *Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-5731-2847
Aditi JainDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Samantha Z BrownDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Alex HaberDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Austin GoetzDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Chunhua XiThe Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York.
Gloria H SuThe Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York.
Liang XuDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas.
James PoseyDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Wei JiangDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Charles J YeoDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Talia GolanOncology institute, Chaim Sheba Medical Center, Tel Aviv, Israel.
Michael J PishvaianMD Anderson Cancer Center, Houston, Texas.
Jonathan R BrodyDepartment of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. jonathan.brody@jefferson.edu.
Thomas Jefferson University · USColumbia University Irving Medical Center · USTel Aviv University · ILThe University of Texas MD Anderson Cancer Center · USUniversity of Kansas · US
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM008562 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WALTER K KRAFT, Scott A. Waldman · 1995 to 2026
$10.2MThe Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin SignalingR01CA217207 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2017 to 2021
$2.4MThe role of wild-type KRAS in the context of tumor profession and metastasisR01CA178445 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2015 to 2019
$2.2MTargeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9MNCI NIH HHS P30 CA056036NCI NIH HHS R01 CA178445NCI NIH HHS R01 CA212600NCI NIH HHS R01 CA217207NIGMS NIH HHS T32 GM008562
Abstract
Mutation or promoter hypermethylation of
Indexed as
Adaptor Proteins, Signal TransducingAminopyridinesAnimalsBenzimidazolesCell Line, TumorDisease Models, AnimalELAV-Like Protein 1FemaleHumansMiceMice, NudePancreatic NeoplasmsTranscription FactorsTransfectionYAP-Signaling ProteinsabemaciclibAdaptor Proteins, Signal TransducingAminopyridinesBenzimidazolesELAV-Like Protein 1Transcription FactorsYAP1 protein, humanYAP-Signaling Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.